Carboplatin (NSC 241240)

For research use only. Not for use in humans.

目录号:S1215 别名: JM-8, CBDCA 中文名称:卡铂

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Carboplatin (NSC 241240, JM-8, CBDCA) 是一种DNA合成抑制剂,在 A2780,SKOV-3,IGROV-1,和 HX62细胞中,通过结合到DNA上并干扰细胞修复机制发挥作用。现配现用

规格 价格 库存 购买数量  
RMB 630.25 现货
RMB 1367.43 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Carboplatin (NSC 241240)发表文献80篇:

产品安全说明书

Antineoplastic and Immunosuppressive Antibiotics抑制剂选择性比较

生物活性

产品描述 Carboplatin (NSC 241240, JM-8, CBDCA) 是一种DNA合成抑制剂,在 A2780,SKOV-3,IGROV-1,和 HX62细胞中,通过结合到DNA上并干扰细胞修复机制发挥作用。现配现用
特性 不建议使用DMSO溶解。[6]
靶点
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
体外研究

Carboplatin作用于一组人类卵巢癌细胞系,包括A2780, SKOV3,和 IGROV-1细胞,抑制细胞增殖,IC50分别为6.1 μM, 12.4 μM 和2.2 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfHNk0zPeLCid88US=> MVS3NkBp NWXBeFVZcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
Tca8113/CBP  M1zUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCwPI4zNTJ34pEJ{txO MmnhO|IhcA>? NIDVXFVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/PYM  NYPYPZhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzqNk0zPeLCid88US=> NIj1TWs4OiCq MlXrbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M{HyUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NVA2Lz5{NkGzO|ExPTxxYU6=
SKOV3 M2TDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeyNpU3OCCvZz;tcC=> NWXBbJRpOS13IHS= MWnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{C0N{c,OjZzM{ewOFM9N2F-
SKOV3 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DlcFAuPCEQvHevcYw> NEDEWlMzPC92OD:3NkBp NFzDT5ZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO|M9N2F-
SKOV3 NWrBUIczSXCxcITvd4l{KEG|c3H5 M4q3VVIh|rypL33s NGflWoc1QCCq MnPHbY5lfWOnczDhdI9xfG:|aYO= NVX1[5A3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzPzNpPkK2NVI2Ojd|PD;hQi=>
OSA M36wfmNtd26xZ3XubYMhSXO|YYm= NU\EN4RsOi53L{Wg{txO NX6yNnFWemW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= M3XlS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUGwOlIxLz5{NkGxNFYzODxxYU6=
A549 M{HhbmZ2[3Srb36gRZN{[Xl? M1ntVVAwOjVxNUCg{txO M4X3bFI1KGh? NUGxfppm\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> M1XKS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG3N|E4Lz5{NUmxO|MyPzxxYU6=
H1975 MYTGeYN1cW:wIFHzd4F6 MV:wM|I2NzVyIN88US=> NHzpSmEzPCCq MVXkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi Mn61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
A549 MYHGeYN1cW:wIFHzd4F6 NIDRWmUxNzJ3L{WwJO69VQ>? Mmj3NlQhcA>? M{i3TJVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? M4DpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG3N|E4Lz5{NUmxO|MyPzxxYU6=
H1975 NXW5bo16TnWldHnvckBCe3OjeR?= M2HxPFAwOjVxNUCg{txO MlexNlQhcA>? NF\LXnJ2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
A549 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLBNlUh|ryP MnrUNlQhcA>? NGiwXXJqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 NYT1dWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmyOUDPxE1? NH\GNmYzPCCq M{K0V4lvcGmkaYTzJINmdGxiZ4Lve5Rp M4qwXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG3N|E4Lz5{NUmxO|MyPzxxYU6=
MDA-MB-231 NHPyRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVewMVIzOCEQvHevcYw> MXq3NkBp NV:yU2NzUUN3MNMgQUA5PiEQvF2= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|N{[5NUc,OjV6M{e2PVE9N2F-
T47D MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;mNE0zOjBizsznM41t NYTERYJsPzJiaB?= M3LKdGlEPTEEoE2gOFgvQSEQvF2= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|N{[5NUc,OjV6M{e2PVE9N2F-
LCTCC NXW4empbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwOPMAjeK2VQ>? NUnPOHRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3O|MyPjdpPkK1O|c{OTZ5PD;hQi=>
MCTCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwOPMAjeK2VQ>? Mm\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MegTCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjQS3dKSzVyPUSuNgKBkcL3TR?= NFvpUYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MonoTCC NET5[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe2TlNiUUN3ME21MlbjiIoEtV2= M3PXTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{ezNVY4Lz5{NUe3N|E3PzxxYU6=
MCF7 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\kNlAh|ryP M1XSclczKGh? MVrpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> M4TuZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[5NFI2Lz5{NUe2PVAzPTxxYU6=
A-549  Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvOWnhwOC53IN88US=> NH7sUY0zPCCq NWH3TmFwTE2VT9Mg MXLpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549  NXjzcYZySXCxcITvd4l{KEG|c3H5 NHGxXWcxNjVizszN Mn\TOFghcA>? MkXYSG1UV8Li MoWwd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? MkPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549  MoO5SpVkfGmxbjDBd5NigQ>? M1TRdVAvPSEQvF2= MUe0PEBp NW\MWlJjTE2VT9Mg MVzzbI94eyCjYnXydoFvfCCvaXPyc5R2[nWuZTDkbZNzfXC2aX;u NHy0NHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549  MYLGeYN1cW:wIFHzd4F6 NEPQSWUxNjVizszN MWS0PEBp NXrYXYlITE2VT9Mg MnHRbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> M1yxZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
RMG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHudWJKSzVyPUK4MlghyrFiMz62JI1oN0x? NWnSUWhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O|I3QTF|PD;hQi=>
FN-RMG-1 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\jTFkyUUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0> M3XpXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K2PVE{Lz5{NUeyOlkyOzxxYU6=
RMG-1-hFUT NYfDb|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn0R3hKSzVyPUW4MlEhyrFiMj60JI1oN0x? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
FN-RMG-1-hFUT NGf1PWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjnN3hKSzVyPUGxPE45KMLzIEGzMlghdWdxTB?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
CHP-134  MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HlbFEh|ryP MXXEUXNQyqB? MlrFbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKxJO69VQ>? MY\EUXNQyqB? M3LhR4lvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
CHP-134  MmHwSpVkfGmxbjDBd5NigQ>? MUGxNEDPxE4EoB?= NUHvUZFZTE2VT9Mg MnPvbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NHvpVJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
IMR-32 NGHPWYNHfWO2aX;uJGF{e2G7 NEjrXGgyOCEQvF5CpC=> NFfUfHhFVVORwrC= Mn23bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NYHjNZloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVg1PjNpPkK1OlU5PDZ|PD;hQi=>
A549 NGHZVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XW[lAvOi12MECwJO69VQ>? MlG3O|IhcA>? NGDFcIlKSzVyPUGyOkDDuSB3LkCg{txO Mn[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549/CDDP MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMlIuPDByMDFOwG0> Mkj0O|IhcA>? MV\JR|UxRTJ2MNMgxtHDqDR3Lkeg{txO Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
H460  MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7iNlQhcA>? NW\iSIdDTE2VTx?= M4fLdmlEPTB;Nz65JO69VQ>? MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
H460  NH3DcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVm3Mlkh|ryP NYm2dpg{OjRiaB?= NX;iPYVpTE2VTx?= M3HuPZNpd3e|IHGgdoFlcW:|ZX7zbZRqgmmwZzDl[oZm[3RidH:gXE1z[Xm| M2DjVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm5PVk2Lz5{NUW5PVk6PTxxYU6=
NRK-52E NXHRN3U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXoO|LDqGkEoB?= MorJTWM2OD1zMECgxtEhOTJwOTFOwG0> NW\UUFV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
RGE NYfQXm5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NuKhcMLi Mo\OTWM2OD1{MjFCtUA4NjRizszN NF7rTXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2OVYxOyd-MkW1OlU3ODN:L3G+
NRK-52E MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly1O|LDqGkEoB?= MnW0TWM5OD1zN{mgxtEhQS53IN88US=> Mm\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
RGE M2TCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PvXFczyqCqwrC= NHLEfYhKSzhyPU[zJOKyKDdwNDFOwG0> NViybHptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
SK-OV-3 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUS3NkBp Mln2TWM2OD1zMESuPEDPxE1? NVHEfmUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
ES-2 NUL4VW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPmO|IhcA>? Mof1TWM2OD1zND62JO69VQ>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
OVCAR-8 NVjjTld{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jHVlczKGh? MoTqTWM2OD17Nj6wJO69VQ>? M2W2ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
3AO NULrWIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfQO2o4PzJiaB?= NGX3Sm5KSzVyPU[zMlQh|ryP NVnIN2U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
A2780 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO3U|JUPzJiaB?= NUHPRWVVUUN3ME2xOFUvPyEQvF2= NVzlOpM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
SW626 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSUXo4OiCq M4LnfWlEPTB;OUeuNEDPxE1? NXjadndxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
OVCAR-3 NULqVlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33Vc|czKGh? NXzuSXVXUUN3ME2zNk43KM7:TR?= M1vW[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
A549 NIfyc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDqTWM2OD1zNUGuOVYhyrFiNUOuNFYh|ryP Moe0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
4T1 M4\LOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vIfGlEPTB;OESuOlIhyrFiM{CuNFUh|ryPCjFOwG0> Mn3tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
BALB/3T3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TtTWlEPTB;MUSuN|AhyrFiNj62PEDPxE1? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
B16 NUm4S2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\rOGlEPTB;NkSuN|AhyrFiNj64NUDPxE1? NYG4fnBCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
DU 145 NYfHRVI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5OldVUUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= M4nDXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
FaDu MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? MlPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HCV-29T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LkfGlEPTB;NEiuOVchyrFiMkKuOFkh|ryP M4fQUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
HL-60 M2TQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDlTWM2OD1zMT6xNEDDuSB2LkS3JO69VQ>? M3PKR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
HT-29 NGO4VllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrmeGVKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= NEjTcm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
H146 M2\PPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHl[FlUUUN3ME20PU43yrFzMz6xJO69VQ>? NF;ueo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H187 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDk[mpzUUN3ME2xNk44yrF{Lkeg{txO NXe5RVVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H128 NUXWZ4xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7VVodbUUN3ME2xNFYvPMLzOT62JO69VQ>? M3LjUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H69 M1zjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TibWlEPTB;N{[uPeKyOjdwODFOwG0> Mni5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
H209 M2PRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7TUI54UUN3ME2yOVgvOcLzOUmuPEDPxE1? NX7wcYlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS153 NIDIcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7KcJVKSzVyPUW3MljDuTlwMjFOwG0> M1;JRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H526 NGXQSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXib3FUUUN3ME23MlLDuTFwNzFOwG0> NFf4WmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
DMS114 NFP3T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTh3LklCtVEzNjhizszN MkDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS53 NXPF[4ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjMbFRKSzVyPUG0Ok4zyrF|Nj60JO69VQ>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
HeLa M3;HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPSOU05OCEQvF2= NEj2eotqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NVfj[|lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{PjBpPkK1NVA6OzZyPD;hQi=>
MCF-7 NH3NTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG1MVgxKM7:TR?= NYTFemNrcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NYrwOW1CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{PjBpPkK1NVA6OzZyPD;hQi=>
MDA-MB-231 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV21MVgxKM7:TR?= NUW1UHFQcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M3TFOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|YxLz5{NUGwPVM3ODxxYU6=
CaOV3 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf4O|IhcA>? NIXHW49KSzVyPUi2MlEh|ryP MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jlVlczKGh? NG\zc4NKSzVyPUG3PU42KM7:TR?= NUHaclB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlg5PDlpPkK1NFY5QDR7PD;hQi=>
OVCAR-5 NVzsPZdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\GN4ltPzJiaB?= NGjoToxKSzVyPUe1Mlch|ryP M{exdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
SKOV-3 NVvLO5pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXNVJlZPzJiaB?= MWDJR|UxRTVyNDFOwG0> NF6xblY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-4 NHr0dnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDpZZM4OiCq NGHUZoFKSzVyPUK5NE43KM7:TR?= MnXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-8 M1ztdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnHSJJGPzJiaB?= NU[zUmtMUUN3ME22PVAvOiEQvF2= NEjxeYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxfXltOjRiaB?= NWL3RVZEUUN3ME24N{436oDLwsJihKkyNjRizsznM41t MnPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 M{OxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrJZ48zPCCq M{i1fWlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiyNlQhcA>? MYPJR|UxRTd2OD6w5qCKyrIkgJmxMlEh|rypL33s M3fZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXJVZIzPCCq MU\JR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> NXexUXJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
MA148 NITIWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3LcIQ1QCCq NULaPWxrUUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
A549 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXI[mR1PDhiaB?= Mm\2TWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> NEGzbmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MDA-MB-231 M132XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3MS|Y1QCCq MWfJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES  NFKwe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHROFghcA>? MWLJR|UxRTF7Mz6w5qCKyrIkgJmxMlkh|rypL33s MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MA148 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe3NkBp NIDaTIlKSzVyPUGzMlfjiIoEsfMAjVEvOiEQvHevcYw> NYX2[215RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
A549 NGXCXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6O3ZxPzJiaB?= M3Py[2lEPTB;NkSuN-KBkcLz4pEJNU4yKM7:Zz;tcC=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPzepM4OiCq MmrHTWM2OD17OT615qCKyrIkgJmxMlEh|rypL33s NWmw[IZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
NCI-ADR/RES  NH3he4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDlO|IhcA>? M1;VemlEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
A549 M4rI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwO|IhcA>? M4XEemROW09? MlTVTWM2OD1zNUKuOFA6KM7:TR?= M125flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KxN|I{Lz5{NEeyNVMzOzxxYU6=
NCI-H157 M4jpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXCO|JMPzJiaB?= M2HUSWROW09? NFvJNIdKSzVyPUi5Mlk4PyEQvF2= NGDFdVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyNVMzOyd-MkS3NlE{OjN:L3G+
PC9 NXfGeJRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TEW|czKGh? NIq4UoNISzVyPUexMlbDuTlwNTFCuW0> M{fyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7X[G9VPzJiaB?= NIDrTlhISzVyPUGzOuKyOzFwNjFCuW3DqA>? NGnFPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
PC9 MWHBdI9xfG:|aYOgRZN{[Xl? NIDkRpQyODBiwsXN MnTrO|IhcA>? MX;pcoR2[2W|IHHwc5B1d3Orcx?= M2LaNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549  MmnoRZBweHSxc3nzJGF{e2G7 NVqwRpFqOTByINM1US=> NFOzS5U4OiCq NYr1bGk5cW6mdXPld{BieG:ydH;zbZM> M2TYVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549 NIrmflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6xeGJGOjRiaB?= Mof4TWMyOD1zLkS3OkBvVQ>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR|OU[0N|c9N2F-
H1299 NVj0eGViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y1RlI1KGh? NH3xXY1KSzFyPUCuOFQ{KG6P NIjycFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5OlQ{Pyd-MkSzPVY1Ozd:L3G+
HCC15 NFHD[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqyOEBp NITKUlBKSzFyPUCuN|Q3KG6P NYL0UWxoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
H157 NU\Dd4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPhNoVXOjRiaB?= M{nQUWlEOTB;MD64NUBvVQ>? NV7YfphmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
A2780 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP2TWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MEm2PVMoRjJ2MkC5Olk{RC:jPh?=
A2780cisR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\vdHVKSzVyPUS4MlnjiIoEsfMAjVMvQSEQvF2= NIfvO4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
A2780ZD0473R M1fMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnBOWtKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MEm2PVMoRjJ2MkC5Olk{RC:jPh?=
SKOV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1PGdKSzVyPUSzMlTjiIoEsfMAjVMvQSEQvF2= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyOU[5N{c,OjR{MEm2PVM9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘瘿뙠ෆᾰƌෆĀ㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘瘿삨ՂᾰƌՂĀ㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
体内研究

Carboplatin (60 mg/kg,通过腹腔注射)单独作用于A2780移植瘤,具有适度的抗肿瘤效果,处理第6天,相对肿瘤体积为8.4,对照组为11.9, 且处理第6天,T/C为67%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: A2780, SKOV3, IGROV-1 和 HX62
  • Concentrations: 0 到 200 μM
  • Incubation Time: 72 小时
  • Method:

    MTT实验: 指数生长的A2780, SKOV3, IGROV-1和 HX62卵巢癌细胞接种在96孔板中。加入一系列浓度的Carboplatin,再温育72小时。每组实验按一式三份进行。 Sulforhodamine B (SRB)实验:指数生长的 A2780细胞接种在96孔板中。使用浓度不断增加的17-AAG 和Carboplatin处理细胞96小时。使用浓度不断增加的17-AAG或Carboplatin处理细胞 24小时,研究17-AAG 或 Carboplatin处理序列的效果。选中的第一种药剂处理细胞24小时,确保A2780细胞使用第一种药剂至少处理双倍时间(18-24小时)。使用无菌磷酸盐缓冲液冲洗细胞,然后补充培养基。然后,加入第二种药剂 (第一次24小时未处理细胞的)或培养基,再处理96小时。所有实验按一式三份进行。使用中位数效果分析方法按行之有效的原则分析联合研究的效果。使用内部电子表格计算联用的效果。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: A2780人类卵巢癌细胞系皮下移植到雌性无胸腺NCr裸鼠(nu/nu)的两侧
  • Dosages: ≤60 mg/kg (注意:氯化钠溶液与卡铂混合后出现理化、药动学及药效学等方面的配伍禁忌。)
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 371.25
化学式

C6H12N2O4Pt

CAS号 41575-94-4
储存条件 2年 4°C(避光) 粉末
别名 JM-8, CBDCA

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04907968 Recruiting Drug: XMT-1536 (Upifitamab Rilsodotin)|Drug: Carboplatin Platinum-sensitive Ovarian Cancer (UPGRADE-A) Mersana Therapeutics|IQVIA Biotech June 11 2021 Phase 1|Phase 2
NCT04606914 Recruiting Drug: mirvetuximab soravtansine (MIRV; IMGN853) Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer University of Alabama at Birmingham May 27 2021 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • 回答:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

免费分装抑制剂
Tags: 购买Carboplatin (NSC 241240) | Carboplatin (NSC 241240)供应商 | 采购Carboplatin (NSC 241240) | Carboplatin (NSC 241240)价格 | Carboplatin (NSC 241240)生产 | 订购Carboplatin (NSC 241240) | Carboplatin (NSC 241240)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID